ClinicalTrials.gg
TerminatedNCT07446114FOCUS-CANUpdated Nov 6, 2026

Functional Outcomes and Control Using Synchron BCI - Canada

An interventional study of Stentrode in Neurologic Disorder, ALS and Motor Neuron Disease, sponsored by Synchron, Inc.. Terminated at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionMotor Neuron DiseaseRegistry: Nervous System DiseasesReclassifiedWhy we changed it
Registry
Nervous System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Motor Neuron Disease
Why
  1. The study's listed conditions name Motor Neuron Disease, a narrower term within Nervous System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Synchron, Inc. · Not applicable, Interventional, and Other

How we know

Why this study was terminated
Insufficient recruitment
Updated Nov 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Motor Neuron Disease with a site in Canada — 3 open to participants now, 6 under way, none of them phase 3. Motor Neuron Disease · Canada.

Enrollment
11th of 11
1 · median 54
Started
2026
the only one that year
No phase
2 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Motor Neuron Disease with a site in Canada, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 2 with no phase, and was the 17th registered.

Motor Neuron Disease

203 studies on the registry are indexed under Motor Neuron Disease; 61 are open to participants now.

Browse Motor Neuron Disease studies →

Open to participants now

3 of the 17 studies in Motor Neuron Disease with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 43 Motor Neuron Disease studies recruiting now, 29 (67%) set no upper age limit and 2 (5%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Motor Neuron Disease with a site in Canada, or all of them as a file.
02

Study summary

Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)

Read the detailed description

Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN):

The Synchron BCI motor neuroprosthesis is an implanted brain-computer interface indicated for adults with bilateral upper-limb motor impairment, including Motor Neuron Disease. The Synchron BCI is intended to replace the function of motor neurons by detecting, translating and transmitting motor-related brain signals to restore clinically meaningful control of digital devices.

The Synchron BCI is an implanted BCI device that interfaces with the brain to enable control of digital devices in individuals with bilateral upper-limb motor impairment. The Synchron BCI is designed to record volitional motor-related neural signals from the sensorimotor cortices and translate these signals into digital motor outputs to enable control of digital devices to improve functional independence. The system includes both implantable and non-implantable components. Implantable components are the Stentrode and the Transceiver.

03

Conditions studied

  • Neurologic Disorder
  • ALS
  • Motor Neuron Disease

Browse trials for

Keywords

  • ALS
  • BCI
  • Brain computer interface
  • MND
  • Motor Neuron Disease
04

In context

Motor Neuron Disease Reclassified

203 studies on the registry are indexed under Motor Neuron Disease; 61 are open to participants now.

This study's enrollment of 1 is below the median of 30 across 104 interventional studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

Synchron, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Motor Neuron Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide to participate in the study, in the opinion of the Investigator(s).
  2. Diagnosis of amyotrophic lateral sclerosis or motor neuron disease, with bilateral upper-limb paresis.
  3. Aged 18 years or older.
  4. greater than 12 months post-implantation, in the opinion of the Investigator(s).
  5. Preserved precentral gyrus assessed using CT.
  6. Suitable vascular anatomy, in the opinion of the Investigator(s), assessed using CT venography.
  7. Suitable anatomy for subcutaneous pocket creation.
  8. Able to undergo anesthesia.
  9. Willing and able to comply with requirements, including clinical testing visits and training visits in the home.
  10. Caregiver(s) willing and able to facilitate study visits, including visits at the study site and in the home, and BCI use outside of study visits (e.g., device charging).
  11. Patient and Caregiver fluent in English.
  12. Suitable home environment for BCI training, including an internet connection.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Unrealistic expectations regarding the potential benefits of the device, in the opinion of the Investigator(s).
  2. Active infection or unexplained fever in the 48 hours prior to .
  3. Major psychiatric disorder that may adversely impact the participant's safety or study compliance (e.g., severe depression, psychotic features, personality disorder, severe emotional lability, substance abuse), in the opinion of the Investigator(s).
  4. Dementia or cognitive dysfunction that would impact the participant's ability to participate in study activities, in the opinion of the Investigator(s).
  5. Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).
  6. Known allergy to patient-contacting materials included in the implanted device (listed in Physician Implant Manual).
  7. to angiographic imaging or iodine contrast media.
  8. History of central venous sinus thrombosis.
  9. Recent history of new venous thromboembolic event (in the 6 months prior to implant) or recurrent history of venous thromboembolic disease.
  10. Contraindication to antithrombotic therapy, in the opinion of the Investigator(s).
  11. Participant is at substantially increased risk of infection, including status, recurrent or chronic infection, or poorly controlled diabetes mellitus.
  12. Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.
  13. Currently receiving or expected to require medical treatment that may be precluded by device implant, including magnetic resonance imaging, transcranial magnetic stimulation, electroconvulsive therapy, transcranial ultrasound, shortwave, microwave, and/or therapeutic ultrasound diathermy, or balloon angioplasty or stenting in the target vessel.
  14. Pregnant or breast feeding.
  15. Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.
  16. Patients with ALS due to SOD1 mutations on gene therapy.
  17. Any other disease or disorder that could significantly affect participation in the study, in the opinion of the Investigator(s). Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Other
    Single

    Single Arm

    Device: Stentrode

Interventions

  • DeviceStentrode

    The Stentrode is an endovascular electrode array that senses electrical signals from the sensorimotor cortices.

07

What researchers measure

Primary outcomes

  1. Device-related serious adverse events resulting in death or permanently increased disability up to 90 days after implant.

    Time frame: 3 Months

Secondary outcomes

  1. Device-related serious adverse events resulting in death or permanently increased disability up to 1 year after implant.

    Time frame: 12 Months

  2. Target vessel patency assessed using CT venography at 90 and 365 days after implant.

    Time frame: 3 Months and 12 Months

  3. Device migration assessed using CT venography at 90 and 365 days after implant.

    Time frame: 3 Months and 12 Months

Other outcomes

  1. Time in days from implant to device activation.

    Time frame: Number of days from device implant to device activation, up to 12 months after implant.

  2. Stability of recorded BCI signal, using monthly measurements up to 1 year after device implant.

    Time frame: 12 Months

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Sep 2026, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Dec 2026 → Sep 2026 and completion Jul 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Mar 3, 2026
StartActual
Mar 18, 2026
Primary completionActual
Sep 25, 2026was Dec 2026
CompletionActual
Sep 25, 2026was Jul 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Insufficient recruitment
changed Nov 6, 2026
Primary completion
Dec 2026→Sep 25, 2026 (actual)
Nov 6, 2026
Study completion
Jul 2027→Sep 25, 2026 (actual)
Nov 6, 2026
Enrollment
10 (estimated)→1 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Terminated
    Why stopped Insufficient recruitment
    Primary completion Dec 2026→Sep 25, 2026 (now actual)
    Study completion Jul 2027→Sep 25, 2026 (now actual)
    Enrollment 10 (estimated)→1 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07446114
Lead sponsor
Synchron, Inc.
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Mar 18, 2026
Primary completion
Sep 25, 2026
Completion
Sep 25, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion